GSK commences tender offer for Nuvalent shares
( June 24, 2026, 20:43 GMT | Official Statement) -- MLex Summary: GSK commenced a tender offer to purchase the Class A Common Stock and Class B Common Stock of biopharma company Nuvalent at $124 per share. The offer and withdrawal rights expire July 14, unless the offer is extended or earlier terminated, Nuvalent said in a US securities filing.Statement follows in full....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.